These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 9550942)
1. Endocannabinoids: a new class of vasoactive substances. Randall MD; Kendall DA Trends Pharmacol Sci; 1998 Feb; 19(2):55-8. PubMed ID: 9550942 [TBL] [Abstract][Full Text] [Related]
2. A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery. White R; Hiley CR Br J Pharmacol; 1997 Dec; 122(8):1573-84. PubMed ID: 9422801 [TBL] [Abstract][Full Text] [Related]
3. Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. Randall MD; Kendall DA Eur J Pharmacol; 1997 Sep; 335(2-3):205-9. PubMed ID: 9369375 [TBL] [Abstract][Full Text] [Related]
4. An endogenous cannabinoid as an endothelium-derived vasorelaxant. Randall MD; Alexander SP; Bennett T; Boyd EA; Fry JR; Gardiner SM; Kemp PA; McCulloch AI; Kendall DA Biochem Biophys Res Commun; 1996 Dec; 229(1):114-20. PubMed ID: 8954092 [TBL] [Abstract][Full Text] [Related]
5. The complexities of the cardiovascular actions of cannabinoids. Randall MD; Kendall DA; O'Sullivan S Br J Pharmacol; 2004 May; 142(1):20-6. PubMed ID: 15131000 [TBL] [Abstract][Full Text] [Related]
6. The quest for a vascular endothelial cannabinoid receptor. Kunos G; Bátkai S; Offertáler L; Mo F; Liu J; Karcher J; Harvey-White J Chem Phys Lipids; 2002 Dec; 121(1-2):45-56. PubMed ID: 12505689 [TBL] [Abstract][Full Text] [Related]
8. Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. Herradón E; Martín MI; López-Miranda V Br J Pharmacol; 2007 Nov; 152(5):699-708. PubMed ID: 17704831 [TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacology of endothelium-derived hyperpolarizing factor and anandamide in rat isolated mesentery. Randall MD; McCulloch AI; Kendall DA Eur J Pharmacol; 1997 Aug; 333(2-3):191-7. PubMed ID: 9314035 [TBL] [Abstract][Full Text] [Related]
10. Anandamide and endothelium-derived hyperpolarizing factor act via a common vasorelaxant mechanism in rat mesentery. Randall MD; Kendall DA Eur J Pharmacol; 1998 Apr; 346(1):51-3. PubMed ID: 9617751 [TBL] [Abstract][Full Text] [Related]
11. Cardiovascular effects of cannabinoids. Randall MD; Harris D; Kendall DA; Ralevic V Pharmacol Ther; 2002 Aug; 95(2):191-202. PubMed ID: 12182966 [TBL] [Abstract][Full Text] [Related]
12. Cardiovascular effects of endocannabinoids--the plot thickens. Kunos G; Járai Z; Varga K; Liu J; Wang L; Wagner JA Prostaglandins Other Lipid Mediat; 2000 Apr; 61(1-2):71-84. PubMed ID: 10785543 [TBL] [Abstract][Full Text] [Related]
13. Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries. O'Sullivan SE; Kendall DA; Randall MD Br J Pharmacol; 2004 Jun; 142(3):435-42. PubMed ID: 15148250 [TBL] [Abstract][Full Text] [Related]
14. Endocannabinoids as cardiovascular modulators. Kunos G; Járai Z; Bátkai S; Goparaju SK; Ishac EJ; Liu J; Wang L; Wagner JA Chem Phys Lipids; 2000 Nov; 108(1-2):159-68. PubMed ID: 11106789 [TBL] [Abstract][Full Text] [Related]
15. Effects of hypertension on vasorelaxation to endocannabinoids in vitro. Wheal AJ; Randall MD Eur J Pharmacol; 2009 Jan; 603(1-3):79-85. PubMed ID: 19100733 [TBL] [Abstract][Full Text] [Related]
16. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Járai Z; Wagner JA; Varga K; Lake KD; Compton DR; Martin BR; Zimmer AM; Bonner TI; Buckley NE; Mezey E; Razdan RK; Zimmer A; Kunos G Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14136-41. PubMed ID: 10570211 [TBL] [Abstract][Full Text] [Related]
17. Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. White R; Ho WS; Bottrill FE; Ford WR; Hiley CR Br J Pharmacol; 2001 Oct; 134(4):921-9. PubMed ID: 11606334 [TBL] [Abstract][Full Text] [Related]
18. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390 [TBL] [Abstract][Full Text] [Related]
19. Production and physiological actions of anandamide in the vasculature of the rat kidney. Deutsch DG; Goligorsky MS; Schmid PC; Krebsbach RJ; Schmid HH; Das SK; Dey SK; Arreaza G; Thorup C; Stefano G; Moore LC J Clin Invest; 1997 Sep; 100(6):1538-46. PubMed ID: 9294122 [TBL] [Abstract][Full Text] [Related]
20. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. Molina-Holgado F; Molina-Holgado E; Guaza C; Rothwell NJ J Neurosci Res; 2002 Mar; 67(6):829-36. PubMed ID: 11891798 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]